Loading company
Cumberland Pharmaceuticals Inc.
CPIX · Nasdaq · ·
Next earnings: November 3, 2026
$7.68-1.1%Sep 29 close
- 1M
- -9.3%
- 6M
- +211.7%
- 1Y
- +211.7%
- 5Y
- +256.3%
CPIX · Nasdaq · ·
Next earnings: November 3, 2026
$7.68-1.1%Sep 29 close
Cumberland Pharmaceuticals Inc. is scheduled to report next on November 3, 2026. The date comes from Nasdaq’s earnings calendar, and companies sometimes move it.
The quarter ending June 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toJun 30, 2026 | 3 months toJun 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $8.8M | $10.8M | -18.79% |
| Profit | -$4.3M | -$740.7K | -477.31% |
| Profit per share | -$0.29 | -$0.05 | -480.00% |
| Free Cash Flow | $130.5K | $817.3K | -84.04% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Releases land after the close or before the open, so the move is the session that follows.
Cumberland Pharmaceuticals Inc. is the largest biopharmaceutical company founded and headquartered in Tennessee and is focused on developing innovative products that improve the quality of patient care. The company is advancing a clinical pipeline of late-stage product candidates across multiple therapeutic areas with significant unmet medical needs. Cumberland's Phase 2 clinical programs are evaluating ifetroban in patients with Duchenne Muscular Dystrophy, Systemic Sclerosis, Idiopathic Pulmonary Fibrosis and Cancer Metastasis.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Cumberland Pharmaceuticals Inc.’s Item 2.02 8-K filed August 4, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
Cumberland Pharmaceuticals Inc. has no earnings call transcript available.